Research into and clinical study support for COVID-19 treatments
First written in FY2020. 2 of 4 entries say "Advanced", first in FY2021-Q1. Latest entry: FY2022-Q1.
0 other companies' latest entry also says "Dropped".
- FY2022-Q1DroppedAnnual report
「We had been conducting a Phase III trial in Japan of the protease inhibitor Foipan Tablets for COVID-19, but discontinued development because no efficacy was demonstrated.」
The Phase III trial of Foipan Tablets for COVID-19 was discontinued because no efficacy was demonstrated, ending development of the treatment. - FY2021-Q3AdvancedAnnual report
「*7: We began a Phase III trial in Japan of Foipan Tablets for COVID-19.」
The clinical trial of Foipan Tablets for COVID-19 advanced to Phase III. - FY2021-Q1AdvancedAnnual report
「*7: We began a clinical trial for COVID-19 involving the protease inhibitor Foipan Tablets.」
The start of a clinical trial of Foipan Tablets for COVID-19 was described as progress in the development pipeline. - FY2020First statedAnnual report
「To contribute to the research and development of treatments and other products, we have begun a clinical trial using camostat mesilate, an oral protease inhibitor used to treat chronic pancreatitis and postoperative reflux esophagitis. We are also providing formulations for clinical research in response to requests from medical and research institutions in Japan and overseas to conduct clinical studies.」
As part of its response to COVID-19, the company described the start of a clinical trial of camostat mesilate and the provision of formulations for clinical research.